Névine Zariffa, Founder NMD Group LLC, co-wrote this post with Sarah Jarvis
The coronavirus pandemic has tested us all. It’s been humbling to have so little direct power to respond to it. For colleagues in drug development, their mission has never been so critical. Some are focused on the treatment or prevention of COVID-19, while others assess and manage the impact of the pandemic on their plans to help patients with diseases other than COVID-19. How should study teams handle the disruptions to ongoing non-COVID-19 clinical trials? How should sponsors ensure that the dissemination of scientific information is both appropriate and timely through their medical affairs organizations? When and how should companies reinitiate evidence generation activities? Such decisions benefit from scenario planning.